<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01223534</url>
  </required_header>
  <id_info>
    <org_study_id>QFT-ECC-01</org_study_id>
    <secondary_id>2009-017430-49</secondary_id>
    <secondary_id>TRA-126</secondary_id>
    <nct_id>NCT01223534</nct_id>
  </id_info>
  <brief_title>QuantiFERON®-TB Gold In-Tube for the Diagnosis of Tuberculosis Infection in Contact Tracing Study.</brief_title>
  <acronym>OPTIMIST</acronym>
  <official_title>Comparison of Two Strategies for Therapeutic Decision-making in Tuberculosis Contact Tracing: a Standard Strategy Based on Tuberculin Skin Test (TST) Alone vs TST Combined With QuantiFERON®-TB Gold In-Tube (QFT-IT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitari de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cellestis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitari de Bellvitge</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothesis: a combined strategy of tuberculin skin test (TST) followed by QuantiFERON-TB Gold
      In-Tube (QFT-IT) to confirm positivity (tuberculosis infection,in contact-tracing study will
      allow avoiding unnecessary preventive treatment without increasing rates of tuberculosis
      cases among contacts screened.

      Aim of the study: to compare a combined strategy of the TST and the QFT-IT with TST alone for
      the diagnosis of tuberculosis infection and for therapeutic decision in contact tracing
      study.

      Design and setting: Prospective, multicentre, comparative study in 12 hospitals in Spain.

      Study population: 870 subjects, household contacts of patients with culture positive
      pulmonary and/or laryngeal tuberculosis will be randomized to one of two strategies: Arm A
      (standard practice), in which treatment decisions will be based on the TST result, and Arm B
      (experimental), in which treatment decisions will be based on the QFT result.

      Interventions: participants in arm A will undergo TST; participants in arm B will undergo
      TST, and, in case of a positive result, QFT-IT as well. Participants with positive TST (arm
      A) and positive QFT-IT (arm B) will be diagnosed with tuberculosis infection and will be
      treated with isoniazid for 6 months. All participants will be followed for two years.

      End-points of evaluation: development of tuberculosis and proportion of subjects for whom
      treatment is prescribed in each arm.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2010</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of tuberculosis.</measure>
    <time_frame>Assessment of primary end-point: 24 months after randomization.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prescription of treatment.</measure>
    <time_frame>The day 0 (visit 2) after randomization.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">871</enrollment>
  <condition>Latent Tuberculosis Infection</condition>
  <arm_group>
    <arm_group_label>Arm A, Standard practice, TST</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants allocated to screening as stablished by current practice (TST)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B, Experimental, TST plus QFT-IT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants allocated to screening with TST, and if positive, followed by QFT-IT to confirm tuberculosis infection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Preventive treatment with Isoniazid.</intervention_name>
    <description>If TST positive: participant will be treated with Isoniazid 300 mg/d, for 6 months.</description>
    <arm_group_label>Arm A, Standard practice, TST</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Preventive treatment with Isoniazid</intervention_name>
    <description>If QFT-IT positive, Isoniazid 300 mg/d, for 6 months.</description>
    <arm_group_label>Arm B, Experimental, TST plus QFT-IT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years.

          -  Close contact of a pulmonary and/or laryngeal tuberculosis case.

          -  Written informed consent.

        Exclusion Criteria:

          -  HIV infection.

          -  Immunosuppression other than HIV, such as decompensated liver disease, chronic renal
             failure, corticosteroids treatment, malignancy under chemotherapy therapy.

          -  Prior tuberculosis or positive TST.

          -  Strain resistant to Isoniazid (index case).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel Santin, MD</last_name>
    <role>Study Director</role>
    <affiliation>Bellvitge University Hospital, Bellvitge Institute for Biomedical Research (IDIBELL)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bellvitge University Hospital, IDIBELL</name>
      <address>
        <city>L'Hospitalet de Llobregat, Barcelona</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2010</study_first_submitted>
  <study_first_submitted_qc>October 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2010</study_first_posted>
  <last_update_submitted>May 26, 2016</last_update_submitted>
  <last_update_submitted_qc>May 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitari de Bellvitge</investigator_affiliation>
    <investigator_full_name>Miguel Santín Cerezales</investigator_full_name>
    <investigator_title>PhD, MD</investigator_title>
  </responsible_party>
  <keyword>Tuberculosis</keyword>
  <keyword>Latent tuberculosis infection</keyword>
  <keyword>Tuberculin skin test</keyword>
  <keyword>Interferon-gamma release assays</keyword>
  <keyword>Contact-tracing study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Latent Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isoniazid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

